Semaglutide and Tirzepatide Clinical Trials 2026: What the Research Actually Shows

Q: How much weight do people lose on semaglutide?

The STEP 1 trial, published in the New England Journal of Medicine in 2021, evaluated branded once-weekly injectable semaglutide 2.4mg in 1,961 adults with obesity or overweight with at least one weight-related comorbidity. Over 68 weeks, participants on semaglutide achieved an average body weight reduction of approximately 14.9% compared to 2.4% in the placebo group. 86.4% of semaglutide participants achieved at least 5% weight loss versus 31.5% in placebo. These are trial averages for an FDA-approved branded medication in a controlled clinical setting. They are not applicable to compounded semaglutide, to any individual patient outside the trial, or to the programs offered by telehealth platforms. Individual responses to GLP-1 medications vary substantially based on clinical, behavioral, and genetic factors.

Q: Is tirzepatide more effective than semaglutide for weight loss?

Head-to-head clinical trial data for branded medications supports a meaningful efficacy advantage for tirzepatide over semaglutide in weight reduction. The SURMOUNT-5 trial compared once-weekly branded tirzepatide 10mg or 15mg to branded semaglutide 2.4mg in adults with obesity or overweight without type 2 diabetes over 72 weeks. Average weight reduction was approximately 20.2% for tirzepatide versus 13.7% for semaglutide — a difference of approximately 47% greater weight loss with tirzepatide in this study population. The mechanism explanation is tirzepatide's dual GLP-1 and GIP receptor agonism compared to semaglutide's single receptor target. Gastrointestinal side effect profiles were broadly similar, though tirzepatide showed slightly lower nausea rates in some trial analyses. These comparisons apply to FDA-approved branded medications at specific doses used in the trials. Compounded versions of these medications have not been evaluated in head-to-head comparative trials.

Q: Do GLP-1 medications have long-term risks?

GLP-1 receptor agonist medications including semaglutide and tirzepatide carry established risk profiles from their clinical trial programs and post-marketing surveillance. The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation — typically most pronounced during dose titration and diminishing with continued therapy. The most serious established risk is thyroid C-cell tumor development, observed in rodent studies; semaglutide and tirzepatide carry a black box warning for thyroid C-cell tumors and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2. Pancreatitis has been reported, though causal relationship remains under evaluation. Gallbladder disease including gallstones and cholecystitis has been observed at higher rates in treated populations than in placebo groups. Lean mass loss alongside fat mass loss is a documented concern in longer-term use; clinical guidelines recommend resistance exercise and adequate protein intake during treatment. Long-term cardiovascular outcome data for semaglutide is available from the SELECT trial published in 2023, which showed a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease — one of the most clinically significant findings in the field.

Q: What is the difference between clinical trial results and real-world outcomes for GLP-1 medications?

Clinical trials for GLP-1 medications like STEP 1 and SURMOUNT-1 involve tightly controlled conditions: participants are screened for eligibility, receive standardized medication doses, follow consistent titration protocols, and are monitored regularly with behavioral support components. Real-world outcomes typically differ from trial averages. Discontinuation rates in real-world settings are substantially higher than in trials — some observational data suggests 30–50% of patients discontinue GLP-1 medications within the first year, often due to cost, side effects, or limited access to ongoing clinical support. Post-marketing observational data from remote GLP-1 programs shows average weight loss of approximately 8–15% over 12 months, somewhat below trial averages, reflecting the impact of non-trial conditions on adherence and outcomes. Weight regain after discontinuation is well-documented; clinical evidence consistently shows that weight returns toward baseline when GLP-1 receptor agonist medications are stopped. This long-term medication dependency is an important consideration patients should discuss with a prescriber before starting.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. SterlingMedicalCenter.org is an independent health research publication. Clinical trial data cited in this article apply to FDA-approved branded medications in controlled research settings and are not applicable to compounded medications or to any individual patient. Always consult a qualified healthcare professional before starting any prescription medication or treatment program.

By SterlingMedicalCenter.org Editorial Team

Quick Answer: The STEP 1 trial (New England Journal of Medicine, 2021) found branded injectable semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. The SURMOUNT-5 trial found that branded tirzepatide produced an average 20.2% reduction, compared with 13.7% for branded semaglutide, over 72 weeks. These figures apply to FDA-approved medications in controlled clinical settings — not to compounded versions, not to telehealth program outcomes, and not to individual patients. Reading them correctly requires understanding trial design, population characteristics, and the gap between trial and real-world conditions.

How to Read Supplement and Medication Research

The weight-loss industry routinely deploys clinical trial citations as marketing proof without disclosing what the trials actually studied. A statistic like “lose up to 24% of your body weight” attached to a compounded semaglutide program is referencing data from branded medication trials — and omitting that the compounded version was not in the trial, that “up to” describes an outlier outcome rather than an average, and that the 24% figure comes from tirzepatide trials, not semaglutide. These are not minor details.

Before evaluating any GLP-1 program, the three questions that matter are: What medication was studied? At what dose? Under what conditions? Answering these three questions about any cited statistic reveals whether the number applies to the program being marketed. The analysis below applies this framework to the key clinical trials in the semaglutide and tirzepatide evidence base.

The Dose Math Framework for GLP-1 Research

GLP-1 receptor agonist research involves dose-response relationships that matter when evaluating outcomes. Semaglutide is studied and prescribed across multiple dose ranges: lower doses (0.5–1.0mg weekly) for type 2 diabetes management, and higher doses (2.4mg weekly as branded Wegovy) specifically studied for chronic weight management. The STEP 1 trial used 2.4mg weekly — the maximum approved dose for weight management. Studies using lower doses of branded semaglutide report smaller average weight reductions.

Tirzepatide dose escalation in the SURMOUNT trials reached 10mg and 15mg weekly. Outcomes at 5mg — the lowest studied dose — were substantially smaller than at the maximum dose. When evaluating any compounded GLP-1 program, the dose structure and titration ceiling are significant for understanding which outcomes the available research supports at the prescribed dose.

Semaglutide Research Overview: The STEP Trial Program

The STEP (Semaglutide Treatment Effect in People with Obesity) program was a series of phase 3 randomized controlled trials that established the evidence base for branded injectable semaglutide 2.4mg as a chronic weight management medication.

STEP 1 (2021, NEJM): 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes. 68 weeks, once-weekly subcutaneous branded semaglutide 2.4mg versus placebo, with lifestyle intervention in both arms. Result: mean body weight change of −14.9% in the semaglutide group versus −2.4% in the placebo group. 86.4% of semaglutide participants achieved ≥5% weight loss; 69.1% achieved ≥10%; 50.5% achieved ≥15%. These are the figures most widely cited in GLP-1 marketing materials.

STEP 4 (2021, JAMA): After an initial 20-week run-in period on semaglutide in which participants lost an average 10.6% of body weight, participants were randomized to continue semaglutide or switch to placebo for an additional 48 weeks. The placebo group regained 6.9 percentage points of body weight, compared with an additional −7.9% in the continuation group. STEP 4 established the rebound evidence: weight returns when semaglutide is discontinued. This finding is clinically significant for anyone considering a long-term medication commitment.

SELECT (2023, NEJM): 17,604 adults with pre-existing cardiovascular disease and overweight or obesity, without type 2 diabetes. Weekly branded semaglutide 2.4mg versus placebo over a mean of 39.8 months. Semaglutide reduced the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 20% compared to placebo. This was the first large-scale cardiovascular outcome trial demonstrating a benefit for a GLP-1 weight management medication beyond glucose control — a finding that has meaningfully expanded prescribing rationale for the class in high-cardiovascular-risk patients.

Tirzepatide Research Overview: The SURMOUNT Trial Program

The SURMOUNT program evaluated branded tirzepatide (Zepbound) as a chronic weight management medication in adults with obesity or overweight, building the FDA approval package that led to tirzepatide's weight management approval in November 2023.

SURMOUNT-1 (2022, NEJM): 2,539 adults with obesity or overweight with at least one weight-related comorbidity (excluding type 2 diabetes). 72 weeks of once-weekly branded tirzepatide at 5mg, 10mg, or 15mg versus placebo with lifestyle intervention. Mean weight reduction was −15.0% at 5mg, −19.5% at 10mg, and −20.9% at 15mg, versus −3.1% for placebo. The 15mg result, with an average weight loss of approximately 20.9%, represented the highest average reduction reported in a major GLP-1 phase 3 trial at the time of publication.

SURMOUNT-5 (2025): A head-to-head comparison of branded tirzepatide (10mg or 15mg) versus branded semaglutide 2.4mg in adults with obesity or overweight without type 2 diabetes, 72 weeks. The average weight reduction was approximately 20.2% with tirzepatide versus approximately 13.7% with semaglutide. This is the only major randomized trial directly comparing the two medications in a weight management population and represents the current clinical benchmark for understanding the relative efficacy of the two GLP-1 agonist classes.

How These Findings Apply to Compounded GLP-1 Programs

The clinical trials summarized above evaluated FDA-approved branded medications at specific doses manufactured under FDA manufacturing standards. Three distinctions matter when translating this research to compounded GLP-1 programs offered through telehealth platforms.

First, compounded medications are not FDA-approved finished drug products. They have not undergone the bioequivalence testing, clinical evaluation, or manufacturing quality controls required for FDA approval. A compounded semaglutide or tirzepatide preparation may contain the same active ingredient as its branded counterpart — but “same active ingredient” does not confirm equivalent pharmacokinetics, bioavailability, or clinical outcomes. No compounded GLP-1 medications have been evaluated in randomized controlled trials comparable to STEP or SURMOUNT.

Second, the dose ranges used in clinical trials may not align with those prescribed in telehealth programs. Most telehealth programs use titration protocols that begin at low doses and may not reach the trial's maximum doses for all patients. Weight reduction outcomes are dose-dependent.

Third, real-world adherence differs substantially from trial adherence. A 2025 retrospective study of 339 participants in a remote GLP-1 program (Second Nature, published in JMIR) reported an average 12-month weight loss of approximately 8–12% — meaningful but below the STEP 1 and SURMOUNT-1 trial averages, consistent with the expected gap between tightly controlled trial conditions and real-world telehealth delivery.

For further context on the 2026 regulatory landscape affecting compounded GLP-1 products, see SMC's analysis of FDA enforcement activity in the compounded GLP-1 space. For an analysis of specific telehealth programs, see our GLP-1 telehealth program comparison.

What This Means for Program Selection

The clinical trial evidence base for GLP-1 receptor agonist medications is among the most robust in weight management pharmacology. The STEP and SURMOUNT programs represent well-designed, large-sample randomized controlled trials with long follow-up periods and consistent findings. For patients who are clinically eligible and are considering a GLP-1 prescription program, this evidence base supports the mechanism as sound and the magnitude of effect as meaningful.

The appropriate use of this research when evaluating a specific program requires distinguishing between what the trials showed for branded medications at specific doses and what can reasonably be expected from a compounded version at a telehealth-managed dose. Honest evaluation acknowledges this distinction rather than importing trial averages wholesale into program marketing. Our full review of the Novi GLP-1 program applies this framework directly to one program's published terms and verified clinical evidence. The GLP-1 safety guide covers contraindications, interaction risks, and monitoring considerations before any patient starts this class of medication.

Frequently Asked Questions

How much weight do people lose on semaglutide?

The STEP 1 trial of branded injectable semaglutide 2.4mg reported an average body weight reduction of approximately 14.9% over 68 weeks in a population with obesity or overweight. 50.5% of participants achieved at least 15% weight loss. These figures apply to FDA-approved branded semaglutide at 2.4mg weekly in a controlled clinical trial. They are not applicable to compounded semaglutide, to specific telehealth programs, or to any individual patient. Real-world observational data from remote GLP-1 programs suggests average outcomes of approximately 8–12% over 12 months, reflecting differences in population, adherence, and program structure.

Is tirzepatide more effective than semaglutide for weight loss?

Head-to-head trial data for branded medications in SURMOUNT-5 found approximately 20.2% average weight loss with tirzepatide versus 13.7% with semaglutide over 72 weeks in adults with obesity or overweight without type 2 diabetes — a clinically meaningful difference attributed to tirzepatide's dual GLP-1 and GIP receptor agonism. This comparison applies to FDA-approved branded medications at trial doses. No head-to-head trial data exists for compounded versions of these medications.

Do GLP-1 medications have long-term risks?

Established risks include gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) most prominent during dose titration; a black box warning for thyroid C-cell tumors (contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2); increased gallbladder disease risk; and lean mass loss during treatment. Long-term cardiovascular benefit in high-risk populations was demonstrated in the SELECT trial for semaglutide. Weight regain after discontinuation is well-documented. All risks and benefits should be reviewed with a licensed prescriber.

What is the difference between clinical trial results and real-world outcomes for GLP-1 medications?

Clinical trials involve controlled conditions, standardized dosing, selected populations, and high-intensity monitoring that rarely replicate real-world telehealth delivery. STEP 1 and SURMOUNT-1 averages reflect ideal-condition outcomes. Real-world data from remote GLP-1 programs shows average outcomes approximately 30–40% below trial averages, primarily due to higher discontinuation rates, variable adherence, and absence of the intensive behavioral support components present in trials. Patients should assess program structure — clinician access, titration support, side effect management — alongside pricing when comparing telehealth programs.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. All clinical trial data cited applies to FDA-approved branded medications in controlled research settings. Outcomes are not applicable to compounded medications, to specific telehealth programs, or to any individual patient. Always consult a qualified healthcare professional before starting any prescription medication or treatment program.